aibioProtagonist authorizes $300 million share buyback after two drug approvals
Tickers PTGX
The peptide drug developer will fund repurchases from cash and royalty income. It held $849.5 million at June 30, before $275 million in Takeda payments due in the fourth quarter.
Key facts
- Company
- Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
- News type
- Financings
- Primary source
- Protagonist Therapeutics via Newswire
Protagonist Therapeutics said on September 8 that its board authorized the company to repurchase up to $300 million of its common stock. Purchases may be made in the open market or through other transactions, including a Rule 10b5-1 plan, and the program does not oblige the company to buy any set number of shares.
The company said it will fund buybacks from cash on hand and from royalties and other payments it receives from Takeda for Mimrylo (rusfertide) and from Johnson & Johnson for Icotyde (icotrokinra). Protagonist is not obliged to buy any set number of shares, and it can change, suspend or end the program at any time.
The details
Protagonist had $849.5 million in cash, cash equivalents and marketable securities at June 30. That figure does not include $275 million it earned from Takeda in August, made up of a $200 million opt-out payment and a $75 million approval milestone. The company expects to receive those payments in the fourth quarter of 2026.
The release gave no executive quotes and no timetable. It said timing and amounts will depend on market conditions, the share price, royalty and milestone receipts and other uses of capital.
The buyback had been flagged. When it reported first-quarter results on May 5, CEO Dinesh Patel said Protagonist looked forward to implementing an efficient capital return strategy at the appropriate time.
Context
Protagonist is a peptide discovery company that has licensed out its two late-stage drugs. J&J won FDA approval for Icotyde, an oral IL-23 receptor blocker for plaque psoriasis, in March, triggering a $50 million milestone. Takeda won approval for Mimrylo in polycythemia vera on August 28. Protagonist receives tiered royalties of 6% to 10% on Icotyde and 14% to 29% on Mimrylo.
The company has turned profitable on those payments. It reported net income of $162.8 million in the second quarter, mostly from recognizing the first $200 million Takeda opt-out payment. Its 10-Q said it does not anticipate a need for additional funding in the near term.
At the same time, Protagonist is increasing its own spending. It told investors that research and development costs will rise significantly in the second half of 2026 as it moves PN-881, its wholly owned oral IL-17 antagonist, into a phase 2b psoriasis program and funds obesity, hematology and discovery programs.
What it means for investors
This buyback comes from a company whose own pipeline is still early. It says management sees more cash coming in than the internal programs will need for now, and it chose to return some of it rather than wait. The June 30 cash plus the $275 million Takeda payment comes to about $1.12 billion before spending, so the authorization is roughly a quarter of that.
The trade-off is flexibility. Money used for buybacks is not available for deals or for later-stage trials of PN-881 or the obesity peptides, which are in phase 1 or earlier. The royalty streams that fund the plan are new and depend on two partners' launches, which Protagonist does not control. The 10-Q warns that early in a launch, royalty revenue may lag prescriptions while reimbursement is set up.
What to watch
Protagonist expects the $275 million Takeda payments in the fourth quarter. PN-881 phase 2b dosing is planned for early in the first quarter of 2027. Disclosures in the next 10-Q will show how many shares, if any, were bought.